Abbott Receives Xinlay “Not Approvable” Letter

Letter follows a unanimous recommendation by FDA’s Oncologic Drugs Advisory Committee against approving atrasentan for treatment of hormone refractory prostate cancer in patients with disease metastatic to bone.